Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 5
2009 3
2010 6
2011 3
2012 5
2013 1
2014 2
2015 4
2016 4
2017 1
2018 7
2019 11
2020 10
2021 16
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

67 results
Results by year
Filters applied: . Clear all
Page 1
Prostate carcinogenesis: inflammatory storms.
de Bono JS, Guo C, Gurel B, De Marzo AM, Sfanos KS, Mani RS, Gil J, Drake CG, Alimonti A. de Bono JS, et al. Among authors: gurel b. Nat Rev Cancer. 2020 Aug;20(8):455-469. doi: 10.1038/s41568-020-0267-9. Epub 2020 Jun 16. Nat Rev Cancer. 2020. PMID: 32546840 Review.
Genomics of lethal prostate cancer at diagnosis and castration resistance.
Mateo J, Seed G, Bertan C, Rescigno P, Dolling D, Figueiredo I, Miranda S, Nava Rodrigues D, Gurel B, Clarke M, Atkin M, Chandler R, Messina C, Sumanasuriya S, Bianchini D, Barrero M, Petermolo A, Zafeiriou Z, Fontes M, Perez-Lopez R, Tunariu N, Fulton B, Jones R, McGovern U, Ralph C, Varughese M, Parikh O, Jain S, Elliott T, Sandhu S, Porta N, Hall E, Yuan W, Carreira S, de Bono JS. Mateo J, et al. Among authors: gurel b. J Clin Invest. 2020 Apr 1;130(4):1743-1751. doi: 10.1172/JCI132031. J Clin Invest. 2020. PMID: 31874108 Free PMC article. Clinical Trial.
Targeting the p300/CBP Axis in Lethal Prostate Cancer.
Welti J, Sharp A, Brooks N, Yuan W, McNair C, Chand SN, Pal A, Figueiredo I, Riisnaes R, Gurel B, Rekowski J, Bogdan D, West W, Young B, Raja M, Prosser A, Lane J, Thomson S, Worthington J, Onions S, Shannon J, Paoletta S, Brown R, Smyth D, Harbottle GW, Gil VS, Miranda S, Crespo M, Ferreira A, Pereira R, Tunariu N, Carreira S, Neeb AJ, Ning J, Swain A, Taddei D; SU2C/PCF International Prostate Cancer Dream Team, Schiewer MJ, Knudsen KE, Pegg N, de Bono JS. Welti J, et al. Among authors: gurel b. Cancer Discov. 2021 May;11(5):1118-1137. doi: 10.1158/2159-8290.CD-20-0751. Epub 2021 Jan 11. Cancer Discov. 2021. PMID: 33431496 Free PMC article.
Characterizing CDK12-Mutated Prostate Cancers.
Rescigno P, Gurel B, Pereira R, Crespo M, Rekowski J, Rediti M, Barrero M, Mateo J, Bianchini D, Messina C, Fenor de la Maza MD, Chandran K, Carmichael J, Guo C, Paschalis A, Sharp A, Seed G, Figueiredo I, Lambros M, Miranda S, Ferreira A, Bertan C, Riisnaes R, Porta N, Yuan W, Carreira S, de Bono JS. Rescigno P, et al. Among authors: gurel b. Clin Cancer Res. 2021 Jan 15;27(2):566-574. doi: 10.1158/1078-0432.CCR-20-2371. Epub 2020 Sep 28. Clin Cancer Res. 2021. PMID: 32988971 Free PMC article.
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
Neeb A, Herranz N, Arce-Gallego S, Miranda S, Buroni L, Yuan W, Athie A, Casals T, Carmichael J, Rodrigues DN, Gurel B, Rescigno P, Rekowski J, Welti J, Riisnaes R, Gil V, Ning J, Wagner V, Casanova-Salas I, Cordoba S, Castro N, Fenor de la Maza MD, Seed G, Chandran K, Ferreira A, Figueiredo I, Bertan C, Bianchini D, Aversa C, Paschalis A, Gonzalez M, Morales-Barrera R, Suarez C, Carles J, Swain A, Sharp A, Gil J, Serra V, Lord C, Carreira S, Mateo J, de Bono JS. Neeb A, et al. Among authors: gurel b. Eur Urol. 2021 Feb;79(2):200-211. doi: 10.1016/j.eururo.2020.10.029. Epub 2020 Nov 8. Eur Urol. 2021. PMID: 33176972 Free article.
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R, Syndikus I, Ralph C, Jain S, Varughese M, Parikh O, Crabb S, Robinson A, McLaren D, Birtle A, Tanguay J, Miranda S, Figueiredo I, Seed G, Bertan C, Flohr P, Ebbs B, Rescigno P, Fowler G, Ferreira A, Riisnaes R, Pereira R, Curcean A, Chandler R, Clarke M, Gurel B, Crespo M, Nava Rodrigues D, Sandhu S, Espinasse A, Chatfield P, Tunariu N, Yuan W, Hall E, Carreira S, de Bono JS. Mateo J, et al. Among authors: gurel b. Lancet Oncol. 2020 Jan;21(1):162-174. doi: 10.1016/S1470-2045(19)30684-9. Epub 2019 Dec 2. Lancet Oncol. 2020. PMID: 31806540 Free PMC article. Clinical Trial.
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.
Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, Ferreira A, Lambros MBK, Seed G, Yuan W, Dolling D, Welti JC, Neeb A, Sumanasuriya S, Rescigno P, Bianchini D, Tunariu N, Carreira S, Sharp A, Oyen W, de Bono JS. Paschalis A, et al. Among authors: gurel b. Eur Urol. 2019 Oct;76(4):469-478. doi: 10.1016/j.eururo.2019.06.030. Epub 2019 Jul 22. Eur Urol. 2019. PMID: 31345636 Free PMC article.
NKX3.1 as a marker of prostatic origin in metastatic tumors.
Gurel B, Ali TZ, Montgomery EA, Begum S, Hicks J, Goggins M, Eberhart CG, Clark DP, Bieberich CJ, Epstein JI, De Marzo AM. Gurel B, et al. Am J Surg Pathol. 2010 Aug;34(8):1097-105. doi: 10.1097/PAS.0b013e3181e6cbf3. Am J Surg Pathol. 2010. PMID: 20588175 Free PMC article.
CD38 in Advanced Prostate Cancers.
Guo C, Crespo M, Gurel B, Dolling D, Rekowski J, Sharp A, Petremolo A, Sumanasuriya S, Rodrigues DN, Ferreira A, Pereira R, Figueiredo I, Mehra N, Lambros MBK, Neeb A, Gil V, Seed G, Terstappen L, Alimonti A, Drake CG, Yuan W, de Bono JS; International SU2C PCF Prostate Cancer Dream Team. Guo C, et al. Among authors: gurel b. Eur Urol. 2021 Jun;79(6):736-746. doi: 10.1016/j.eururo.2021.01.017. Epub 2021 Mar 5. Eur Urol. 2021. PMID: 33678520 Free PMC article.
67 results